{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000146","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.647010+00:00","generated_at":"2026-05-31T14:28:21.986425+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care","bullets":["ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.","ATEV also demonstrated significantly longer hemodialysis duration over 12 months (p=0.0162).","Company plans to discuss potential market authorization pathway with FDA soon.","More adverse events were reported in the ATEV arm compared to the fistula arm.","Over 800,000 Americans have end-stage renal disease; ATEV is an off-the-shelf bioengineered vessel."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000146","json":"https://secwatch.observer/filing/0001818382-24-000146.json","markdown":"https://secwatch.observer/filing/0001818382-24-000146.md","text":"https://secwatch.observer/filing/0001818382-24-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/0001818382-24-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/huma-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:28:21.986425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}